Q-omics provides the consensus-scored MYO1F profile across patient tissues and cancer cell-line models. MYO1F expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, MYO1F is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, MYO1F protein abundance shows 27,166 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KIRC, and LSCC as cancer lineages where MYO1F shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYO1F — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYO1F survival associations across molecular data types. MYO1F RNA expression shows survival associations in the most cancer types (23), followed by mutation status (9) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYO1F RNA expression–survival associations across cancer types. High MYO1F expression shows unfavorable associations in LGG and UVM, but favorable associations in HNSC, SKCM, UCEC and CESC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for MYO1F RNA expression.
This table summarizes MYO1F tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MYO1F. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYO1F shows lower tumor expression in LUAD and LUSC and higher tumor expression in KIRC, KIRP, STAD and THCA. The KIRC box plot shows higher MYO1F RNA expression in tumor versus normal tissue (log2 FC = +2.256, t-test p < 0.001).
This table shows molecular features associated with MYO1F in patient tissues and cancer cell lines. In patient samples, MYO1F shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MYO1F RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LIVER and SOFT_TISSUE.
